Lilly said patients must refill their prescriptions of the two higher-dose vials within 45 days of their first fill to get the same pricing, and would otherwise have to pay as much as $699 for ...

Lilly Offers Weight-Loss Drugs in Vials at a Discount to Fight Competition By Patrick Wingrove and Sriparna Roy (Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for an Opdivo (nivolumab) and Yervoy (ipilimumab ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

Shares of the Indianapolis-based drugmaker rose 2.3% to $902.42. The launch of Lilly's vials expands options for patients who choose to pay cash through the drugmaker's direct-to-consumer website ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch of people I know (including me) have gotten sick ...

BMS’ Opdivo is approved in more than 65 countries. Credit: Amy Lutz/Shutterstock. The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

Bristol Myers Squibb has won Food and Drug Administration priority review for its application seeking approval of the combination of its Opdivo and Yervoy cancer drugs for the early treatment of ...

Bristol Myers (BMY) Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a potential first-line treatment option for adult and ...

NEW YORK – Bristol Myers Squibb said Monday that the US Food and Drug Administration has accepted its supplemental biologics license application (sBLA) seeking approval for the checkpoint inhibitor ...

Bristol Myers Squibb (BMS) has shared positive overall survival (OS) results from a late-stage study of its Opdivo (nivolumab) combination in non-small cell lung cancer (NSCLC). The phase 3 ...

Credit: JHVEPhoto / Shutterstock. Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used ...